VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs) Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results